NEW YORK, July 31, 2026, 18:03 EDT
Apnimed Inc. NASDAQ:APMD finished its first session on Nasdaq at $25, representing a 56.25% increase from its IPO price of $16. Market data indicated a market capitalization close to $950 million. The regular session had ended, but after-hours trading was still ongoing. The stock was last quoted at $23, reflecting an 8% drop from the closing price.
After increasing the offering by two million shares, the basic market capitalization approaches $1.0 billion. This figure represents approximately 69% of Inspire Medical Systems’ NASDAQ:INSP value, which stands at $1.44 billion. Apnimed does not have any approved products. The FDA is expected to reach its decision on February 28, 2027.
The tape on the first day reflected robust demand and broad price discovery.
| Debut measure | Result | Versus $16 IPO |
|---|---|---|
| Opening price | $22.00 | +37.5% |
| Intraday high | $29.15 | +82.2% |
| Intraday low | $16.12 | +0.8% |
| Closing price | $25.00 | +56.25% |
| After-hours, 17:57 EDT | $23.00 | +43.75% |
| Regular-session volume | 3.44 million | 28.7% of base offer |
The company issued 12 million shares, up from the 10 million initially offered.
However, the stock finished significantly under its $29.15 high. The after-hours drop occurred on just around 18,700 shares, which reduces the significance of the move.
The valuation bridge illustrates the amount of approval value generated during a single session.
| Valuation measure | Value |
|---|---|
| Market capitalization reported | $950 million |
| Estimated adjusted basic market value | About $1.00 billion |
| Estimated adjusted value at IPO price | About $640 million |
| Increase in value on first day | About $360 million |
| Cash in June plus total IPO gross proceeds, preliminary | $364.8 million |
| Closing value to cash and proceeds ratio | About 2.7 times |
The revised numbers increase the reported share count by two million, resulting in a total of 38 million shares. These figures do not include the underwriters’ option of 1.8 million shares. Offering costs and debt changes are also not part of this calculation.
Cash is not the only factor behind the closing valuation. Apnimed disclosed preliminary cash holdings of $172.8 million as of June 30. The IPO brings in an additional $192 million in gross proceeds prior to fees. The filing states the company does not have any approved products or commercial revenue.
The FDA began its formal review of the AD109 application in July. Chief Executive Kevin Lind described the development as “an important milestone” in expanding patient access to treatment. The agency set a target action date for February 2027. PR Newswire
The clinical package showed comparable efficacy differences across both key studies.
| Phase 3 measure | AD109 | Placebo | Difference |
|---|---|---|---|
| SynAIRgy average AHI decline | 44.1% | 17.6% | 26.5 percentage points |
| LunAIRo average AHI decline | 33.7% | 7.3% | 26.4 percentage points |
| SynAIRgy adverse event withdrawal | 21.2% | 3.1% | 18.1 percentage points |
| SynAIRgy all-cause withdrawal prior to week 26 | 34.3% | 16.3% | 18.0 percentage points |
| SynAIRgy fatigue result | No significant advantage | — | — |
AHI tracks the number of breathing pauses per hour. Percentage-point gaps are derived from reported and submitted outcomes.
The efficacy margin remained unchanged. Tolerability varied. Discontinuations due to adverse events in SynAIRgy occurred at a rate almost sevenfold higher than with placebo. Fatigue also showed no significant statistical difference.
The stock is currently traded alongside established OSA companies and a major pharmaceutical rival.
| Company | OSA approach | Status | July 31 market value |
|---|---|---|---|
| Apnimed NASDAQ:APMD | Oral AD109, taken once nightly | Under FDA review | $950 million reported; estimated $1.0 billion adjusted |
| Inspire Medical Systems NASDAQ:INSP | Surgically implanted airway stimulation | Commercially available | $1.44 billion |
| ResMed (NYSE:RMD) | CPAP devices and connected equipment | Commercially available | $30.74 billion |
| Eli Lilly NYSE:LLY | Zepbound injection | FDA-approved for specific OSA patients | $1.03 trillion |
Lilly’s market value takes into account its broad range of drugs. It should not be viewed as a direct OSA peer.
Zepbound has been cleared for use in adults with obesity who have moderate-to-severe OSA. Apnimed has submitted data from studies involving mild, moderate and severe forms of the condition. If it secures approval and real-world patients tolerate it well, the oral formulation may expand available treatment options.
The offering gained momentum throughout the week. Apnimed increased the base offering to 12 million shares from 10 million. It also priced shares at the upper end of the stated range. The Nasdaq Composite rose 1.6% over the week, but this was well below Apnimed’s performance on debut.
The offering is set to close on August 3, kicking off activity next week. Eli Lilly is scheduled to release its second-quarter earnings on August 5. Investors might monitor commentary regarding overall Zepbound demand, as OSA represents just one use case.
Risks: The FDA could postpone, limit, or decline approval. Apnimed’s prospects rest on a single clinical asset and the company reports no commercial income. Elevated discontinuation rates could hamper uptake. The slight after-hours reversal suggests volatile initial trading.
